CompletedPHASE1, PHASE2NCT03529877

Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa

Studying Dystrophic epidermolysis bullosa

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: RHEACELL GmbH & Co. KG
Principal Investigator: Jakub Tolar, MD, PhD
University of Minnesota, Masonic Cancer Center and Medical Center
Intervention: allo-APZ2-EB(biological)
Enrollment: 16 enrolled
Eligibility: 0-55 years · All sexes
Timeline: 2019 – 2021

Study locations (6)

University of Minnesota, Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States
EB-Haus Austria; Salzburger Landeskliniken (SALK); Paracelsus Medizinische Privatuniversität Salzburg (PMU), Salzburg, Austria
Hôpital Saint-Louis; Département de dermatologie, Paris, France
Department of Dermatology, Medical Center-University of Freiburg, Freiburg im Breisgau, Germany
King's College London; St John's Institute of Dermatology;, London, United Kingdom
Great Ormond Street Hospital; Dermatology Department, London, United Kingdom

Collaborators

FGK Clinical Research GmbH · Granzer Regulatory Consulting & Services · Ticeba GmbH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03529877 on ClinicalTrials.gov

Other trials for Dystrophic epidermolysis bullosa

Additional recruiting or active studies for the same condition.

See all trials for Dystrophic epidermolysis bullosa →

← Back to all trials